Skyline Diagnostics

The partners are developing and optimizing an algorithm that assesses the likelihood of a patient's cancer progressing to metastasis.

The companies partnered last month to develop new personalized cancer diagnostics using the Helomics D-Chip bioinformatics platform.

The new algorithm, called TOPSPIN, complements the company's MMprofiler test. It is considering making TOPSPIN-generated data available to its MMprofiler patients.

The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.

The genetic test determines risk levels and prognosis for patients with multiple myeloma based on the SKY92 gene signature.

Dutch molecular diagnostics company SkylineDx recently established a presence in Boston to bolster its outreach to the North American market.

SkylineDx has acquired all assets from recently shuttered Skyline Diagnostics and will continue to develop and commercialize the latter's menu of microarray-based tests, BioArray News has learned.

Kurt Schmidt has been appointed CEO of Skyline Diagnostics. Schmidt joins Skyline from Agendia, where he had served as chief financial officer since 2009.

This story was originally posted on June 22.

Pages

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.